CD8A and neoplasm: Another study showed that 89Zr-labeled anti-CD8 immuno-PET was a sensitive tool for detecting changes in systemic and tumor-infiltrating CD8 expression in preclinical syngeneic tumor immunotherapy models including immune checkpoint blockade antibody therapy (anti-PD-L1) [28].